ClinicalTrials.gg
CompletedNCT03159572HITOMIUpdated Nov 21, 2024

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations

An observational study in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Completed at 1 site in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
996
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 113 studies in Ovarian Neoplasms with a site in Japan — 36 open to participants now, 63 under way, 26 of them phase 3. Ovarian Neoplasms · Japan.

Started
2017
with 4 others
Observational
7 of 113
1 open now
Registered
40th of 113
by date

Among the 113 studies in Ovarian Neoplasms with a site in Japan, this one is one of 5 that started in 2017, is one of 7 observational ones, and was the 40th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

36 of the 113 studies in Ovarian Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Ovarian Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

To investigate the frequency and clinical significance of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including Fallopian tube cancer and primary peritoneal cancer).

Read the detailed description

In this study, investigators plan to clarify the frequency of Homologous Recombination Deficiency (HRD) in Japanese patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

And investigators will also investigate whether HRD-positive ovarian cancer patients show the clinical characteristics of highly platinum-sensitivity and good prognosis, comparing to HRD-negative ovarian cancer patients.

In addition, it is planned to investigate any association between Progression Free Survival (PFS) / Platinum-Sensitivity and germline mutation in Breast Cancer Susceptibility Gene (BRCA1/2 gene) in ovarian cancer patients who can provide the patients' gBRCA1/2 gene information for this study.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Keywords

  • Ovarian cancer
  • Fallopian tube cancer
  • Primary peritoneal cancer
  • Germline Breast Cancer Susceptibility Gene (BRCA1/2 gene)
  • Homologous Recombination Deficiency (HRD)
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult ovarian cancer patients who provided written informed consent including providing tumor tissue specimens before surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who can approve and sign it. Patients who show their will to participate in this study and can sign the informed consent forms by themselves.
  2. Patients who are clinically diagnosed as having ovarian cancer and can provide written informed consent before the surgery.
  3. Patients who can provide tumor tissue specimens. (except ascites cytology and cell block specimens)
  4. Patients who are 20 years old and over at the enrollment.
  5. Patients with Performance status (PS): 0-2.

Exclusion criteria

Exclusion Criteria:

  1. Patients with active concomitant * except breast cancer.

    *Includes synchronous multiple cancer and metachronous multiple cancer with less than 5 years of disease free survival. However, excludes skin basal cell carcinoma, skin squamous cell carcinoma, and any other curable lesions with local therapy such as carcinoma in situ or intramucosal carcinoma.

  2. Patients who are diagnosed as any other acute/chronic, physically/mentally severe diseases and judged by the primary physician as inappropriate to enroll this study because of safety reasons or any influence to study outcomes.
  3. Any other cases that are inappropriate to enroll this study, judged by study principal investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
996 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Ovarian cancer group

    Patients who are diagnosed with ovarian cancer and have a plan of surgery.

06

What researchers measure

Primary outcomes

  1. Frequency of HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)

    When all tumor samples are stored at ToMMo after the term of registration, DNA are extracted from frozen tumor tissue. These extracted tumor DNA, after confirmed at inspection body that it has constant qualities, are examined for HRD by DNA target sequencing.

    Time frame: 17 months

Secondary outcomes

  1. Association between Progression Free Survival (PFS) / Response Rate and HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)

    PFS is calculated from registration date to the date diagnosed as progression or the date of death from any cause, whichever comes earlier. Response rate(RR) is determined the rate of patients who are evaluated of best overall response as CR(complete response) or PR(partial response) from those with measurable disease (based on Guidelines to Evaluate the Response to Treatment in Solid Tumors, RESIST). Association between PFS/RR and HRD which is clarified as primary outcome is assessed.

    Time frame: 48 months

  2. Association between Progression Free Survival (PFS) / Response Rate and germline mutation in BRCA1/2 gene in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)

    PFS is calculated from registration date diagnosed as having progression or the date of death from any cause, whichever comes earlier. Response rate(RR) is determined the rate of patients who are evaluated of best overall response as CR(complete response) or PR(partial response) from those with measurable disease (based on Guidelines to Evaluate the Response to Treatment in Solid Tumors, RESIST). Association between PFS/RR and gBRCA1/2 gene information from patients who can provide their gBCRA1/2 gene information with their informed consent, is evaluated.

    Time frame: 48 months

07

Study locations

1 site
  • Niigata University Graduate School of Medical and Dental Sciences
    Niigata city, Niigata Prefecture 951-8510, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Feb 2022, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2017
First posted
May 18, 2017
StartActual
Mar 28, 2017
Primary completionActual
Feb 16, 2022
CompletionActual
Feb 16, 2022
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03159572
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators
Department of Obstetrics and Gynecology, School of Medicine, Niigata University, Japanese Gynecologic Oncology Group (JGOG), Tohoku Medical Megabank Organization(ToMMo)
Responsible party
Sponsor
First posted
May 18, 2017
Start date
Mar 28, 2017
Primary completion
Feb 16, 2022
Completion
Feb 16, 2022
Last update
Nov 21, 2024

Study contacts

Takayuki Enomoto, MD, Ph.D
study chair · Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion